Academic Journal
Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials
| Τίτλος: | Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials |
|---|---|
| Συγγραφείς: | Oshima, M, Buizen, L, Jongs, N, Levin, A, Chertow, GM, Wheeler, DC, Heerspink, HJL, Arnott, C, Jardine, MJ, Mahaffey, KW, Pollock, C, Herrington, WG, Perkovic, V, Neuen, BL |
| Πηγή: | Clinical Journal of the American Society of Nephrology , 20 (9) pp. 1206-1214. (2025) |
| Στοιχεία εκδότη: | Ovid Technologies (Wolters Kluwer Health) |
| Έτος έκδοσης: | 2025 |
| Συλλογή: | University College London: UCL Discovery |
| Περιγραφή: | Background: Unplanned hospitalization, irrespective of cause, is a meaningful outcome for patients, caregivers, clinicians and health systems. The effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on all-cause hospitalization in patients with chronic kidney disease (CKD) has not been systematically evaluated. / Methods: We conducted a post-hoc analysis of the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial to evaluate the effect of canagliflozin on non-elective all-cause hospitalization using Cox proportional hazards models, with recurrent events analysis to assess effects on first and subsequent hospitalizations. We performed inverse variance weighted meta-analysis of three placebo-controlled SGLT2 inhibitor CKD-focused trials to assess the relative and absolute effects of SGLT2 inhibitors on first and subsequent all-cause hospitalizations overall and across clinically relevant subgroups. For analyses of cause-specific hospitalization, adverse events that were reported by investigators but not adjudicated were used. / Results: Over a median follow-up of 2.6 years, 3015 hospitalizations occurred among 1543 of 4401 (35%) participants in the CREDENCE trial. Compared with placebo, canagliflozin reduced the risk of first all-cause hospitalization (hazarrd ratio [HR] 0.88, 95% confidence interval [CI] 0.80-0.98; p=0.02) and first and subsequent hospitalizations (HR 0.86, 95% CI 0.76-0.96; p=0.007). In a meta-analysis of three placebo-controlled SGLT2 inhibitor CKD-focused trials, SGLT2 inhibitors reduced the risk of first and subsequent hospitalizations from any cause by 15% (HR 0.85, 95% CI 0.78-0.95; p<0.001), with consistent effects irrespective of diabetes, baseline kidney function and albuminuria (all P-interactions >0.50). Reductions were driven by hospitalizations due to infection, cardiac, renal or urinary, and metabolism or nutritional disorders. We estimated that SGLT2 inhibition in CKD would prevent 36 (95% CI 13-56) unplanned ... |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | text |
| Γλώσσα: | English |
| Relation: | https://discovery.ucl.ac.uk/id/eprint/10211921/ |
| Διαθεσιμότητα: | https://discovery.ucl.ac.uk/id/eprint/10211921/3/Wheeler_CJASN%20all-cause%20hospitalization%20R1%20clean%2020250502.pdf https://discovery.ucl.ac.uk/id/eprint/10211921/ |
| Rights: | open |
| Αριθμός Καταχώρησης: | edsbas.DC2931EE |
| Βάση Δεδομένων: | BASE |
| Η περιγραφή δεν είναι διαθέσιμη |